Summary
This study is testing a new treatment for people with multiple myeloma. The trial is for people whose cancer has come back (relapsed) or not responded to previous treatment (recurrent).
The study is looking at the safety of the treatment (side effects) and how well it works in controlling the cancer.
Who may be able to take part?
You may be eligible if:
- you are an adult with relapsed/refractory multiple myeloma (R/R MM)
- have already had certain treatments, including BCMA-targeted therapies (such as CAR-T or antibody drug conjugates)
Study details
Participants in this study will receive a combination of two medicines: etentamig, an investigational drug being studied that is given through a drip (IV), and iberdomide (a tablet taken by mouth that affects the immune system). Doctors will test different levels of these medicines to find the safest and most effective combination.
The study will include about 135 adults worldwide and has two parts:
- Part 1: participants receive gradually increasing doses to help find a safe dose
- Part 2: the treatment is studied further at selected dose levels
The study is expected to run for a long period (around 10+ years).
If you join the study, you will need to attend regular visits to a hospital or clinic. At these visits, you will have blood tests, medical check-ups, and questionnaires, and you will be closely monitored for side effects and how the cancer responds to treatment. This trial may involve more frequent visits and tests than standard treatment.